PMVP - PMV Pharmaceuticals, Inc. Stock Analysis | Stock Taper

SCREENER COMPARE ANY 2 STOCKS

PMVP

PMV PHARMACEUTICALS, INC.

NASDAQ

$1.22

▼ DOWN 1.61% (-0.02)

KEY STATISTICS

Market Cap$65.06 M

52w High$1.88

52w Low$1.02

Dividend Yield—

Frequency—

P/E-0.82

Volume90.89K

Shares Out.53.33M

COMPANY

LEADERSHIP

David H. Mack

CHIEF EXECUTIVE

David H. Mack

COMPENSATION 2026

Salary$628,461

Stock Awards$0

Incentive Plan Pay$284,410

All Other Comp.$0

Total$1,665,191

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 25, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

54

PRICE TARGET

Target High$5.00

Target Low$5.00

Target Median$5.00

Target Consensus$5.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.—

NOV

11

WED

PRICE

$1.22 ▼ DOWN 1.61% (−$0.02)

About PMV Pharmaceuticals, Inc.

https://www.pmvpharma.com ↗

PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53 mutations, including its lead candidate PC14586 for the Y220C mutation.

INDUSTRY

Biotechnology

A PRODUCT PMV PHARMACEUTICALS, INC. IS KNOWN FOR

rezatapopt (PC14586)

rezatapopt (PC14586)

Rezatapopt is a first-in-class oral drug candidate targeting the Y220C mutation to selectively reactivate p53, advancing precision oncology for patients with various advanced solid tumors.

COMPETITORS

COMPETITOR

ETFS HOLDING THIS STOCK

ETFS HOLDING

14

LISTED HERE

4

RANKED BY POSITION SIZE

0.01% · 162.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED

70.00%

HOLDERS

96

TOP 12 OF 96 · RANKED BY POSITION SIZE

Orbimed Advisors LLC

6.0M sh · $8.37M

Bml Capital Management, LLC

5.3M sh · $6.6M

Tang Capital Management LLC

4.9M sh · $6.17M

Arrowmark Colorado Holdings LLC

3.3M sh · $4.62M

Sio Capital Management, LLC

3.1M sh · $3.81M

Euclidean Capital LLC

2.6M sh · $3.26M

Eversept Partners, LP

2.3M sh · $2.91M

Acadian Asset Management LLC

2.2M sh · $2.75M

Vanguard Group Inc

2.2M sh · $2.71M

Two Sigma Investments, LP

1.9M sh · $2.34M

Adage Capital Partners Gp, L.L.C.

1.9M sh · $2.31M

Interwest Venture Management Co

1.6M sh · $9.92M

RATINGS SNAPSHOT

Overall rating: B-

Discounted Cash Flow4

Return On Equity1

Return On Assets1

Debt To Equity4

Price To Earnings1

Price To Book4

Overall Score3

INSIDER TRADES

★

DIRECTOR

LEVINE ARNOLD J

Purchase · 42.0K shares

2026-06-04

★

DIRECTOR

Gallagher Carol Giltner

Purchase · 42.0K shares

2026-06-04

★

DIRECTOR

FLOWERS KIRSTEN

Purchase · 42.0K shares

2026-06-04

★

DIRECTOR

BAUM CHARLES M

Purchase · 42.0K shares

2026-06-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY

OUTPERFORM 1

1 GRADES IN THE LAST 12 MONTHS

Oppenheimer OUTPERFORM

SECTORS PEERS

PEER	PRICE
RLMD	$4.33	COMPARE
IMUX	$15.40	COMPARE
CBUS	$1.65	COMPARE
BMEA	$1.73	COMPARE
VXRT	$0.50	COMPARE
ACRV	$2.06	COMPARE
ATYR	$0.54	COMPARE
TCRX	$0.75	COMPARE